What Happened? Shares of biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) fell 17.4% in the afternoon session after the ...

I think that's the case with Vertex. Here are seven reasons why Vertex is a no-brainer stock to buy on the dip.

Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) reported in Q2 CY2025, with sales up 12.1% year on year to $2.96 billion ...

Vertex Pharmaceuticals (NASDAQ:VRTX) shares fell in premarket trading on Tuesday after the company's VX-993 failed to meet ...

Vertex Pharmaceuticals (NASDAQ:VRTX) shares plunged on Tuesday despite the company posting second quarter revenue and adjusted profit above expectations. The stock is down 17% in early trade after the ...

Over the last five years, Vertex's stock has displayed a trend of positive one-day returns in 58% of cases following earnings ...

Vertex Pharmaceuticals Inc.’s bad news from a phase II pain study and separately on the regulatory front caused shares ...

Shares of CRISPR Therapeutics (NASDAQ:CRSP) continued to drop in the premarket on Tuesday after the Swiss biotech posted lower-than-expected Q2 2025 financials, as investors focused on sales from its ...

Vertex Pharmaceuticals Inc (VRTX) reports a 12% revenue increase and successful product launches, while addressing challenges ...

Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) will be reporting earnings this Monday after the bell. Here’s what to ...

U.S. stock futures traded modestly higher late Sunday, pointing to a rebound from the jobs data-induced weakness on Friday.

Vertex Pharmaceuticals (VRTX) closed at $468.41 in the latest trading session, marking a +1.64% move from the prior day. This change outpaced the S&P 500's 0.3% loss on the day. Meanwhile, the Dow ...